We demonstrate that combining SB225002 (a potent, selective and non-peptide CXCR2 antagonist) with PD1 blockade and partial irradiation (LDRT + HDRT) further improves tumor control and mouse survival. The gene discussed is CXCR2; the disease is neoplasm.